Adona Medical Begins First Human Study of Novel Heart Failure Shunt

Adona Medical, a company specializing in heart failure solutions under the Shifamed portfolio, has announced a significant milestone with the successful first-in-human use of its innovative interatrial shunt in patients suffering from heart failure. These initial procedures were conducted by Dr. George Khabeishvili at the Tbilisi Heart and Vascular Clinic in the Republic of Georgia, with support from renowned US cardiologists Dr. Gagan Singh and Dr. Edris Aman.

Dr. Gagan Singh, who serves as the Clinical Cardiovascular Research Unit Director at the University of California, Davis, expressed his enthusiasm about this groundbreaking technology. He emphasized that heart failure is a condition that necessitates ongoing management, and the Adona implant represents a significant advancement in device therapy solutions. The shunt’s ability to dynamically adjust interatrial flow based on the patient's specific hemodynamic needs marks a substantial improvement over current static shunt technologies.

The Adona interatrial shunt is distinguished by its adjustable flow channel, which can be resized post-implantation using a proprietary induction catheter. This feature allows for a more tailored approach to treatment, potentially offering better outcomes compared to existing shunt technologies that are limited to a single, fixed geometry. Additionally, the device is equipped with integrated sensors capable of capturing pressure readings from both the left and right atria multiple times a day. This capability provides physicians with a comprehensive understanding of the patient’s hemodynamic status, potentially enhancing medical management through more informed decision-making.

Brian Fahey, Co-Founder and Chief Executive Officer of Adona Medical, highlighted the significance of these initial clinical successes. He sees this achievement as a crucial step towards validating the potential benefits of the Adona technologies for patients suffering from heart failure. Fahey expressed gratitude to the entire Adona team for their dedication and to the clinical collaborators for their valuable insights, which have been instrumental in reaching this milestone.

Adona Medical, Inc., operates as a clinical-stage medical technology company under the Shifamed portfolio. The company focuses on developing next-generation interatrial shunting and remote patient monitoring solutions for patients with advanced heart failure. The Adona shunt is currently an investigational device and has not received approval for use in the United States or elsewhere.

Shifamed, LLC, founded by serial entrepreneur Amr Salahieh, is a medical innovation hub dedicated to creating solutions that enable patients to lead longer and healthier lives. Shifamed emphasizes specialized medical advancements, aiming to transform patient care through innovative technologies.